alpha-hydroxymetoprolol has been researched along with dapsone in 1 studies
| Studies (alpha-hydroxymetoprolol) | Trials (alpha-hydroxymetoprolol) | Recent Studies (post-2010) (alpha-hydroxymetoprolol) | Studies (dapsone) | Trials (dapsone) | Recent Studies (post-2010) (dapsone) |
|---|---|---|---|---|---|
| 59 | 6 | 12 | 5,116 | 379 | 862 |
| Protein | Taxonomy | alpha-hydroxymetoprolol (IC50) | dapsone (IC50) |
|---|---|---|---|
| Myeloperoxidase | Homo sapiens (human) | 0.42 | |
| Dihydrofolate reductase | Pneumocystis carinii | 1.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujita, K; Horai, Y; Ishizaki, T | 1 |
1 other study(ies) available for alpha-hydroxymetoprolol and dapsone
| Article | Year |
|---|---|
Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer.
Topics: Acetylation; Adult; Aged; Aged, 80 and over; Chi-Square Distribution; Dapsone; Disease Susceptibility; Female; Humans; Japan; Male; Metoprolol; Middle Aged; Oxidation-Reduction; Phenotype; Urinary Bladder Neoplasms | 1989 |